Therapeutic efficacy of Genistein-Cytoreg® combination in breast cancer cells

Authors

  • M. M. Johnson Department of Biological Sciences, Department of Biological Sciences, College of Sciences, Florida Atlantic University at Davie, 3200 College Avenue Davie FL 33314
  • K. J. Kumi-Diaka Department of Biological Sciences, Department of Biological Sciences, College of Sciences, Florida Atlantic University at Davie, 3200 College Avenue Davie FL 33314
  • R. Zoeller Department of Exercise and Health Sciences, Florida Atlantic University at Davie 3200 College Avenue Davie FL 33314
  • B. S. Graves Department of Exercise and Health Sciences, Florida Atlantic University at Davie 3200 College Avenue Davie FL 33314
  • K. T. Merchant Department of Biological Sciences, Department of Biological Sciences, College of Sciences, Florida Atlantic University at Davie, 3200 College Avenue Davie FL 33314
  • V. P. Hörmann Department of Biological Sciences, Department of Biological Sciences, College of Sciences, Florida Atlantic University at Davie, 3200 College Avenue Davie FL 33314
  • M. Hassanhi Department of Blood Bank, University of Zulia, Maracaibo

DOI:

https://doi.org/10.31989/ffhd.v2i5.93

Abstract

Background: In spite the heavy investments in therapeutic research breast cancer still impacts the lives of women globally. The projected incidence of new cases of in situ breast cancer in the USA for 2011 is 57,650, with estimated 39,520 deaths. The phytoestrogen, genistein and the synthetic compound, Cytoreg® have been shown to inhibit growth and proliferation in many cancer cell lines. Purpose of the Study: In this study, we investigated the therapeutic efficacy of Cytoreg®-genistein combination on growth inhibition in the MCF-7 human breast cancer cells.

Method: MCF-7 cells were treated with genistein and Cytoreg® single and combination treatments for 24-48hrs; and post treatment chemosensitivity assessed, using: Trypan Blue exclusion and MTT assays for cell viability, Ethidium bromide/Acridine orange to assess apoptosis induction, and FAM Poly-Caspase binding assay for mechanism of action.

Results: The overall data indicated dose- and time-dependent cell death in the MCF-cells and apoptosis as the major means of treatment-induced growth inhibition with all the treatment regimens.

Conclusion: Comparatively, the genistein-Cytoreg® combination treatment was significantly more efficacious in growth inhibition in the MCF cells than either genistein or Cytoreg® alone. Genistein seems to act additively with Cytoreg® in combination treatment-induced apoptosis in MCF-7 cells. The normal human breast epithelial cells were not significantly inhibited by either single or the combination treatments.

Key words: Cytoreg®, Genistein, Combination treatment, MCF- cancer cells, apoptosis

Downloads

Published

2012-05-20

Issue

Vol. 2 No. 5 (2012): May 2012

Section

Research Articles

License

Authors retain the copyright of their articles and grant the Functional Food Center (FFC) and its journals the right of first publication under the terms of the Creative Commons Attribution 4.0 International License.

This license permits unrestricted use, distribution, and reproduction in any medium, including commercial use, provided the original author(s) and source are properly credited. Authors may post and share their published work freely, provided that the original publication in this journal is acknowledged.

By submitting to this journal, authors confirm that their manuscripts are original, not under consideration elsewhere, and that they hold the necessary rights to grant this license. The Functional Food Center encourages open scientific exchange and allows derivative and extended works, provided attribution to the original publication is maintained.